TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ritu Baral’s rating is based on several factors that highlight GH Research’s potential for growth and development. The company is actively engaging with the FDA to address a remaining issue related to rat histology findings, which is crucial for lifting the clinical hold on their GH001 IND. GH Research is leveraging expert consultants and additional data to strengthen their case, indicating a proactive approach to regulatory challenges.
Furthermore, the company’s financial health appears robust, with a cash balance of $293.9 million, providing a runway into 2027. This financial stability, combined with the anticipated start of their Phase 3 TRD program in 2026, positions GH Research well for future advancements. These strategic efforts and financial positioning contribute to Ritu Baral’s Buy rating for GH Research’s stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.